These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27852694)

  • 21. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation.
    Van Den Ham HA; Klungel OH; Leufkens HG; Van Staa TP
    J Thromb Haemost; 2013 Jan; 11(1):107-15. PubMed ID: 23088617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists.
    Lobos-Bejarano JM; Castellanos Rodríguez A; Barrios V; Escobar C; Polo-García J; Del Castillo-Rodríguez JC; Vargas-Ortega D; Lopez-Pineda A; Prieto-Valiente L; Lip GYH;
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28722795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy.
    Takarada K; Sato M; Goto M; Saito A; Ikeda Y; Fujita S; Fuse K; Takahashi M; Oguro T; Matsushita H; Kitazawa H; Okabe M; Abe H; Toba K; Yamashina A; Aizawa Y
    J Cardiol; 2014 Aug; 64(2):127-32. PubMed ID: 24440439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF.
    Washam JB; Holmes DN; Thomas LE; Pokorney SD; Hylek EM; Fonarow GC; Mahaffey KW; Gersh BJ; Kowey PR; Ansell JE; Go AS; Reiffel JA; Freeman JV; Singer DE; Naccarelli G; Blanco R; Peterson ED; Piccini JP
    J Am Heart Assoc; 2018 Sep; 7(18):e008928. PubMed ID: 30371218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management.
    Bahbahani H; AlTurki A; Dawas A; Lipman ML
    BMC Nephrol; 2018 Jan; 19(1):4. PubMed ID: 29310600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation.
    Nguyen MT; Gallagher C; Pitman BM; Emami M; Kadhim K; Hendriks JM; Middeldorp ME; Roberts-Thomson KC; Mahajan R; Lau DH; Sanders P; Wong CX
    Heart Lung Circ; 2020 Aug; 29(8):1122-1128. PubMed ID: 31980393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
    Salim I; Al Suwaidi J; Ghadban W; Salam AM
    Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.
    Baker WL; Cios DA; Sander SD; Coleman CI
    J Manag Care Pharm; 2009 Apr; 15(3):244-52. PubMed ID: 19326955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
    Gallagher AM; Setakis E; Plumb JM; Clemens A; van Staa TP
    Thromb Haemost; 2011 Nov; 106(5):968-77. PubMed ID: 21901239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.
    Potpara TS; Ferro CJ; Lip GYH
    Nat Rev Nephrol; 2018 May; 14(5):337-351. PubMed ID: 29578207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin.
    Huang D; Wong CL; Cheng KW; Chan PH; Yue WS; Wong CK; Ho CW; Wong ICK; Chan EW; Siu CW
    Postgrad Med J; 2018 Apr; 94(1110):207-211. PubMed ID: 29459408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.
    Han SY; Palmeri ST; Broderick SH; Hasselblad V; Rendall D; Stevens S; Tenaglia A; Velazquez E; Whellan D; Wagner G; Heitner JF
    J Electrocardiol; 2013; 46(1):45-50. PubMed ID: 23063241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
    Jones M; McEwan P; Morgan CL; Peters JR; Goodfellow J; Currie CJ
    Heart; 2005 Apr; 91(4):472-7. PubMed ID: 15772203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.